0001127602-18-003874.txt : 20180202 0001127602-18-003874.hdr.sgml : 20180202 20180202211555 ACCESSION NUMBER: 0001127602-18-003874 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180201 FILED AS OF DATE: 20180202 DATE AS OF CHANGE: 20180202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leuthner Brian A CENTRAL INDEX KEY: 0001652973 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 18572629 MAIL ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1600 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edge Therapeutics, Inc. CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 CONNELL DRIVE STREET 2: SUITE 4000 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 300 CONNELL DRIVE STREET 2: SUITE 4000 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2018-02-01 0001472091 Edge Therapeutics, Inc. EDGE 0001652973 Leuthner Brian A 300 CONNELL DRIVE, SUITE 4000 BERKELEY HEIGHTS NJ 07922 1 1 President and CEO Common Stock 2018-02-01 4 S 0 2500 13.14 D 82736 D Common Stock 2018-02-02 4 S 0 2500 12.96 D 80236 D Common Stock 162000 I By Spouse Common Stock 223622 I By Trust The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $12.68 to $13.45 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $12.78 to $13.06 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. /s/ Albert N. Marchio II, attorney-in-fact 2018-02-02